Price T Rowe Associates Inc Aurinia Pharmaceuticals Inc. Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 59,038 shares of AUPH stock, worth $477,027. This represents 0.0% of its overall portfolio holdings.
Number of Shares
59,038
Previous 52,098
13.32%
Holding current value
$477,027
Previous $468,000
1.5%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding AUPH
# of Institutions
239Shares Held
64.9MCall Options Held
1.1MPut Options Held
772K-
Tang Capital Management LLC San Diego, CA10MShares$81 Million5.24% of portfolio
-
Black Rock Inc. New York, NY9.27MShares$74.9 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5MShares$40.4 Million0.61% of portfolio
-
Nea Management Company, LLC Timonium, MD3.97MShares$32.1 Million3.03% of portfolio
-
State Street Corp Boston, MA2.85MShares$23 Million0.0% of portfolio
About Aurinia Pharmaceuticals Inc.
- Ticker AUPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,892,000
- Market Cap $1.15B
- Description
- Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...